Vertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial.

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

ICER's evaluation of Vertex Pharmaceuticals' non-opioid pain drug, Journavx, finds cost-effectiveness related to potential ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

We recently published a list of Jim Cramer Looked At These 23 Stocks Recently. In this article, we are going to take a look ...

Vertex Pharmaceuticals (VRTX) is the second stock to buy for the Nasdaq 100 correction. The biotech stock offers stability ...

Google has launched the experimental Gemini 2.5 Pro model to all free Gemini app users. It features advanced reasoning ...

Bluebird Bio reviews an unsolicited $4.50 per share bid from Ayrmid after agreeing to a $3.00 per share buyout with Carlyle and SK Capital.

Rabies remains a serious public health concern, with thousands of cases reported annually. Vaccination is the most effective ...

Listed 4iG group and space engineering company REMRED topped out a space technology manufacturing centre in Martonvásár, on ...

Industry updates and investment insights—including investor behavior and fundraising advice—were among the topics experts ...

Leading Chinese module manufacturer Trinasolar has developed an 808W solar module that uses perovskite/silicon tandem solar ...